Sentinel Node Biopsy in Early Breast Cancer.
Identifieur interne : 000646 ( PubMed/Checkpoint ); précédent : 000645; suivant : 000647Sentinel Node Biopsy in Early Breast Cancer.
Auteurs : Stefano M M. Basso [Italie] ; Giordano B. Chiara ; Franco LumachiSource :
- Medicinal chemistry (Shariqah (United Arab Emirates)) [ 1875-6638 ] ; 2016.
Descripteurs français
- KwdFr :
- MESH :
- anatomopathologie : Métastase lymphatique, Noeuds lymphatiques, Tumeurs du sein.
- diagnostic : Tumeurs du sein.
- Biopsie de noeud lymphatique sentinelle, Humains, Noeuds lymphatiques, Stade de la tumeur, Tumeurs du sein.
English descriptors
- KwdEn :
- MESH :
- diagnosis : Breast Neoplasms.
- pathology : Breast Neoplasms, Lymph Nodes, Lymphatic Metastasis.
- surgery : Breast Neoplasms, Lymph Nodes.
- Humans, Neoplasm Staging, Sentinel Lymph Node Biopsy.
Abstract
The approach to the axilla is an evolving paradigm, and recognition of the complexity of breast cancer (BC) biology is changing treatment options. The sentinel lymph node biopsy (SLNB) technique is based on the excision and histological examination of the axillary lymph nodes(s), which is assumed to be the first one draining from the primary tumor. SLNB can accurately stage the axilla, and several trials have shown that there are no significant differences in local recurrence and overall survival between patients treated with or without axillary node dissection (ALND) after a negative SLNB. Surgical morbidity was significantly reduced in terms of rates of lymphedema and neuropathy, with reduced hospital stay and better quality of life after the SLNB procedure. ALND can safely be omitted in patients with ≥2 positive nodes who received conservative surgery and radiotherapy, while ALND is still recommended in clinically N1 BCs, in case of ≥3 positive nodes, and when the number of positive nodes would be crucial for the choice of chemotherapy. Micrometastatic disease can be safely managed with SLNB alone, and additional identification of micrometastases with immunohistochemistry does not affect disease-free survival or overall survival. An appropriate management of the axilla is crucial for the outcome of patients with early BC, and SLNB introduction into the clinical practice dramatically changed the surgical treatment, reducing morbidity without decreasing survival. A tailored approach should be suggested in each patient with BC, considering the biology of the tumor rather than nodal involvement.
PubMed: 26567617
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:26567617Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Sentinel Node Biopsy in Early Breast Cancer.</title><author><name sortKey="Basso, Stefano M M" sort="Basso, Stefano M M" uniqKey="Basso S" first="Stefano M M" last="Basso">Stefano M M. Basso</name><affiliation wicri:level="1"><nlm:affiliation>Surgery 1, Department of Surgery, S. Maria degli Angeli Hospital, Via Montereale 24, 33170 Pordenone, Italy. drsteba@tin.it.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Surgery 1, Department of Surgery, S. Maria degli Angeli Hospital, Via Montereale 24, 33170 Pordenone</wicri:regionArea><wicri:noRegion>33170 Pordenone</wicri:noRegion></affiliation></author><author><name sortKey="Chiara, Giordano B" sort="Chiara, Giordano B" uniqKey="Chiara G" first="Giordano B" last="Chiara">Giordano B. Chiara</name></author><author><name sortKey="Lumachi, Franco" sort="Lumachi, Franco" uniqKey="Lumachi F" first="Franco" last="Lumachi">Franco Lumachi</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26567617</idno><idno type="pmid">26567617</idno><idno type="wicri:Area/PubMed/Corpus">000B42</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000B42</idno><idno type="wicri:Area/PubMed/Curation">000B42</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000B42</idno><idno type="wicri:Area/PubMed/Checkpoint">000B42</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000B42</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Sentinel Node Biopsy in Early Breast Cancer.</title><author><name sortKey="Basso, Stefano M M" sort="Basso, Stefano M M" uniqKey="Basso S" first="Stefano M M" last="Basso">Stefano M M. Basso</name><affiliation wicri:level="1"><nlm:affiliation>Surgery 1, Department of Surgery, S. Maria degli Angeli Hospital, Via Montereale 24, 33170 Pordenone, Italy. drsteba@tin.it.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Surgery 1, Department of Surgery, S. Maria degli Angeli Hospital, Via Montereale 24, 33170 Pordenone</wicri:regionArea><wicri:noRegion>33170 Pordenone</wicri:noRegion></affiliation></author><author><name sortKey="Chiara, Giordano B" sort="Chiara, Giordano B" uniqKey="Chiara G" first="Giordano B" last="Chiara">Giordano B. Chiara</name></author><author><name sortKey="Lumachi, Franco" sort="Lumachi, Franco" uniqKey="Lumachi F" first="Franco" last="Lumachi">Franco Lumachi</name></author></analytic><series><title level="j">Medicinal chemistry (Shariqah (United Arab Emirates))</title><idno type="eISSN">1875-6638</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Breast Neoplasms (diagnosis)</term><term>Breast Neoplasms (pathology)</term><term>Breast Neoplasms (surgery)</term><term>Humans</term><term>Lymph Nodes (pathology)</term><term>Lymph Nodes (surgery)</term><term>Lymphatic Metastasis (pathology)</term><term>Neoplasm Staging</term><term>Sentinel Lymph Node Biopsy</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Biopsie de noeud lymphatique sentinelle</term><term>Humains</term><term>Métastase lymphatique (anatomopathologie)</term><term>Noeuds lymphatiques ()</term><term>Noeuds lymphatiques (anatomopathologie)</term><term>Stade de la tumeur</term><term>Tumeurs du sein ()</term><term>Tumeurs du sein (anatomopathologie)</term><term>Tumeurs du sein (diagnostic)</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Métastase lymphatique</term><term>Noeuds lymphatiques</term><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Breast Neoplasms</term><term>Lymph Nodes</term><term>Lymphatic Metastasis</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Breast Neoplasms</term><term>Lymph Nodes</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Neoplasm Staging</term><term>Sentinel Lymph Node Biopsy</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Biopsie de noeud lymphatique sentinelle</term><term>Humains</term><term>Noeuds lymphatiques</term><term>Stade de la tumeur</term><term>Tumeurs du sein</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The approach to the axilla is an evolving paradigm, and recognition of the complexity of breast cancer (BC) biology is changing treatment options. The sentinel lymph node biopsy (SLNB) technique is based on the excision and histological examination of the axillary lymph nodes(s), which is assumed to be the first one draining from the primary tumor. SLNB can accurately stage the axilla, and several trials have shown that there are no significant differences in local recurrence and overall survival between patients treated with or without axillary node dissection (ALND) after a negative SLNB. Surgical morbidity was significantly reduced in terms of rates of lymphedema and neuropathy, with reduced hospital stay and better quality of life after the SLNB procedure. ALND can safely be omitted in patients with ≥2 positive nodes who received conservative surgery and radiotherapy, while ALND is still recommended in clinically N1 BCs, in case of ≥3 positive nodes, and when the number of positive nodes would be crucial for the choice of chemotherapy. Micrometastatic disease can be safely managed with SLNB alone, and additional identification of micrometastases with immunohistochemistry does not affect disease-free survival or overall survival. An appropriate management of the axilla is crucial for the outcome of patients with early BC, and SLNB introduction into the clinical practice dramatically changed the surgical treatment, reducing morbidity without decreasing survival. A tailored approach should be suggested in each patient with BC, considering the biology of the tumor rather than nodal involvement.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26567617</PMID><DateCreated><Year>2016</Year><Month>04</Month><Day>08</Day></DateCreated><DateCompleted><Year>2016</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-6638</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>3</Issue><PubDate><Year>2016</Year></PubDate></JournalIssue><Title>Medicinal chemistry (Shariqah (United Arab Emirates))</Title><ISOAbbreviation>Med Chem</ISOAbbreviation></Journal><ArticleTitle>Sentinel Node Biopsy in Early Breast Cancer.</ArticleTitle><Pagination><MedlinePgn>273-9</MedlinePgn></Pagination><Abstract><AbstractText>The approach to the axilla is an evolving paradigm, and recognition of the complexity of breast cancer (BC) biology is changing treatment options. The sentinel lymph node biopsy (SLNB) technique is based on the excision and histological examination of the axillary lymph nodes(s), which is assumed to be the first one draining from the primary tumor. SLNB can accurately stage the axilla, and several trials have shown that there are no significant differences in local recurrence and overall survival between patients treated with or without axillary node dissection (ALND) after a negative SLNB. Surgical morbidity was significantly reduced in terms of rates of lymphedema and neuropathy, with reduced hospital stay and better quality of life after the SLNB procedure. ALND can safely be omitted in patients with ≥2 positive nodes who received conservative surgery and radiotherapy, while ALND is still recommended in clinically N1 BCs, in case of ≥3 positive nodes, and when the number of positive nodes would be crucial for the choice of chemotherapy. Micrometastatic disease can be safely managed with SLNB alone, and additional identification of micrometastases with immunohistochemistry does not affect disease-free survival or overall survival. An appropriate management of the axilla is crucial for the outcome of patients with early BC, and SLNB introduction into the clinical practice dramatically changed the surgical treatment, reducing morbidity without decreasing survival. A tailored approach should be suggested in each patient with BC, considering the biology of the tumor rather than nodal involvement.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Basso</LastName><ForeName>Stefano M M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Surgery 1, Department of Surgery, S. Maria degli Angeli Hospital, Via Montereale 24, 33170 Pordenone, Italy. drsteba@tin.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiara</LastName><ForeName>Giordano B</ForeName><Initials>GB</Initials></Author><Author ValidYN="Y"><LastName>Lumachi</LastName><ForeName>Franco</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Med Chem</MedlineTA><NlmUniqueID>101240303</NlmUniqueID><ISSNLinking>1573-4064</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008198" MajorTopicYN="N">Lymph Nodes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021701" MajorTopicYN="Y">Sentinel Lymph Node Biopsy</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>05</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>07</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>07</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26567617</ArticleId><ArticleId IdType="pii">MC-EPUB-71874</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Italie</li></country></list><tree><noCountry><name sortKey="Chiara, Giordano B" sort="Chiara, Giordano B" uniqKey="Chiara G" first="Giordano B" last="Chiara">Giordano B. Chiara</name><name sortKey="Lumachi, Franco" sort="Lumachi, Franco" uniqKey="Lumachi F" first="Franco" last="Lumachi">Franco Lumachi</name></noCountry><country name="Italie"><noRegion><name sortKey="Basso, Stefano M M" sort="Basso, Stefano M M" uniqKey="Basso S" first="Stefano M M" last="Basso">Stefano M M. Basso</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000646 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000646 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:26567617
|texte= Sentinel Node Biopsy in Early Breast Cancer.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:26567617" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |